<DOC>
	<DOC>NCT00376259</DOC>
	<brief_summary>This study is being conducted to compare the safety and effectiveness of the investigational medication LdT (telbivudine) used in combination with adefovir dipivoxil (a drug currently approved by the Food and Drug Administration [FDA] for the treatment of hepatitis B virus [HBV]) versus adefovir dipivoxil used alone. The results for patients taking the combination therapy will be compared to the results for patients taking adefovir alone.</brief_summary>
	<brief_title>Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Documented compensated chronic hepatitis B defined by a clinical history compatible with chronic hepatitis B. Previous or current lamivudine treatment HBV DNA &gt; 6 log10 copies/mL Evidence of viral breakthrough Other protocoldefined inclusion criteria may apply. Patient is pregnant or breastfeeding. Patient is coinfected with hepatitis C virus (HCV), hepatitis D virus (HDV), or HIV. Patient has received any antiHBV treatment for HBV infection other than lamivudine in the 12 months before Screening for this study. Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>lamivudine resistance</keyword>
	<keyword>Hepatitis B virus</keyword>
</DOC>